At present, more than 8.4 million potential donors are registered at DKMS worldwide, from which 20 people are donating stem cells or bone marrow every day. Two out of five stem cell donations worldwide are made through DKMS. Every year DKMS gives more than 7,000 blood cancer patients a second chance at life.
Furthermore, DKMS is conducting clinical research. In order to improve donor selection for stem cell transplants and to optimize patient treatment, DKMS and other cooperation partners established the Collaborative Biobank. At the Biobank, transplant centers, collection centers and donor files participate as equal partners. The aim of the Biobank is to provide a stable basis for future research projects to advance the healing of cancer. For this purpose, samples and the associated medical data are collected and made available from both patients and stem cell donors. The special software from DATAMEDRIX enables the registration of patients and donors participating in the Biobank, and the documentation of relevant medical data.
"With the new solution developed by DATAMEDRIX, we are perfectly prepared for future challenges, ensure the best possible data protection and are able to conduct research at the highest scientific level," summarizes Biobank IT manager Henning Baldauf from DKMS.
From Softwaremanufaktur to DATAMEDRIX
Due to the increasing international orientation, a new company name was favored. "The new official brand name DATAMEDRIX now emphasizes the medical focus of our services and solutions," as the CEO Andreas Redl points out.
DATAMEDRIX is a Vienna-based company that has been providing clinical and medical software solutions and software-based services since 2010. Its clients include the “Arbeitsgemeinschaft medikamentöse Tumortherapie” (AGMT), Croma-Pharma GmbH, the Clinical Trials Coordination Centre (KKS), A. Menarini GmbH, Merck GesmbH, Paracelsus Medical Private University (PMU) and Takeda Pharma Austria.